NEW YORK, NY—October 14, 2026—Commercially insured patients with diagnoses of opioid use disorder increased 32.7 percent nationally from 2022 to 2025, according to FAIR Health’s Opioid Tracker. In 2022, there were 449 patients with opioid use disorder diagnoses per 100,000 patients, while in 2025, there were 596. This and other findings were reported today when FAIR Health released its annual update of the Opioid Tracker, a free, interactive tool tracking opioid use disorder among commercially insured patients nationally and state by state. A brief released simultaneously offers a user’s guide to the Opioid Tracker.

A genetic switch that activates immune cells as they fight tumours: this is the new strategy developed by an international research team coordinated by Velia Siciliano at the Istituto Italiano di Tecnologia (IIT – Italian Institute of Technology) in Naples and described in the scientific journal Nature Communications. The study marks another step towards engineering precise and more effective synthetic immunotherapies against solid tumours, such as melanoma and breast cancer.

Cirrhosis once viewed as irreversible, can improve after effective treatment, but recovery may not be complete or permanent. Researchers from China propose recognizing recompensation as a distinct treatment-related disease state and distinguishing stable from unstable recovery. Evidence across liver diseases shows that recompensation improves outcomes compared with persistent decompensation, while some patients later relapse. The framework could support more consistent research, clinical assessment, and long-term surveillance for patients recovering after cirrhosis treatment.